Article open access publication

Genome-Wide Association Study of Prostate Cancer–Specific Survival

Cancer Epidemiology Biomarkers & Prevention, American Association for Cancer Research (AACR), ISSN 1055-9965

Volume 24, 11, 2015

DOI:10.1158/1055-9965.epi-15-0543, Dimensions: pub.1063224189, PMC: PMC5674990, PMID: 26307654,

Authors

Muir, Kenneth (5) (6)
Giles, Graham G (7) (8)
Neal, David E. (4) (15)
Hamdy, Freddie C. (14) (17)
Pashayan, Nora (4) (18)
Stanford, Janet L (19) (20)
Chanock, Stephen (38) (40)
Ma, Jing (42)
Trichopoulou, Antonia (44) (45) (46)
Bueno-De-Mesquita, Bas H (47) (48) (49) (50)
Cox, David G (50) (52)

Affiliations

Organisations

  1. (1) Karolinska Institute, grid.4714.6
  2. (2) Royal Marsden National Health Service (NHS) Foundation Trust, London and Sutton, United Kingdom
  3. (3) Institute of Cancer Research, grid.18886.3f
  4. (4) University of Cambridge, grid.5335.0
  5. (5) University of Manchester, grid.5379.8
  6. (6) University of Warwick, grid.7372.1
  7. (7) University of Melbourne, grid.1008.9
  8. (8) Cancer Council Victoria, grid.3263.4
  9. (9) University of Southern California, grid.42505.36
  10. (10) University of Turku, grid.1374.1
  11. (11) Tampere University, grid.502801.e
  12. (12) Herlev Hospital, grid.411900.d, Capital Region
  13. (13) University of Copenhagen, grid.5254.6, KU
  14. (14) University of Oxford, grid.4991.5
  15. (15) Cancer Research UK Cambridge Institute, grid.470869.4
  16. (16) University of Bristol, grid.5337.2
  17. (17) Nuffield Department of Surgical Sciences, University of Oxford, Oxford, United Kingdom; Faculty of Medical Science, University of Oxford, John Radcliffe Hospital, Oxford, United Kingdom
  18. (18) University College London, grid.83440.3b
  19. (19) Fred Hutchinson Cancer Research Center, grid.270240.3
  20. (20) University of Washington, grid.34477.33
  21. (21) Mayo Clinic, grid.66875.3a
  22. (22) University Hospital Ulm, grid.410712.1
  23. (23) Rechts der Isar Hospital, grid.15474.33
  24. (24) Division of Urologic Surgery, Brigham and Womens Hospital, Dana-Farber Cancer Institute, Boston, Massachusetts
  25. (25) Pomeranian Medical University, grid.107950.a
  26. (26) George E. Wahlen Department of VA Medical Center, grid.413886.0
  27. (27) University of Utah, grid.223827.e
  28. (28) German Cancer Research Center, grid.7497.d
  29. (29) Krebsregister Saarland, grid.482902.5
  30. (30) Moffitt Cancer Center, grid.468198.a
  31. (31) Medical University of Sofia, grid.410563.5
  32. (32) QIMR Berghofer Medical Research Institute, grid.1049.c
  33. (33) University of Porto, grid.5808.5
  34. (34) Portuguese Oncology Institute, grid.418711.a
  35. (35) University of Surrey, grid.5475.3
  36. (36) Queensland University of Technology, grid.1024.7
  37. (37) Australian Prostate Cancer BioResource, Brisbane, Queensland, Australia
  38. (38) National Cancer Institute, grid.48336.3a
  39. (39) Washington University in St. Louis, grid.4367.6
  40. (40) Frederick National Laboratory for Cancer Research, grid.418021.e
  41. (41) American Cancer Society, grid.422418.9
  42. (42) Harvard University, grid.38142.3c
  43. (43) University of Hawaii at Manoa, grid.410445.0
  44. (44) Academy of Athens, grid.417593.d
  45. (45) Hellenic Health Foundation, grid.424637.0
  46. (46) National and Kapodistrian University of Athens, grid.5216.0
  47. (47) National Institute for Public Health and the Environment, grid.31147.30
  48. (48) University Medical Center Utrecht, grid.7692.a
  49. (49) University of Malaya, grid.10347.31
  50. (50) Imperial College London, grid.7445.2
  51. (51) Danish Cancer Society, grid.417390.8
  52. (52) Cancer Center of Lyon, grid.462282.8
  53. (53) Oslo University Hospital, grid.55325.34

Description

BACKGROUND: Unnecessary intervention and overtreatment of indolent disease are common challenges in clinical management of prostate cancer. Improved tools to distinguish lethal from indolent disease are critical. METHODS: We performed a genome-wide survival analysis of cause-specific death in 24,023 prostate cancer patients (3,513 disease-specific deaths) from the PRACTICAL and BPC3 consortia. Top findings were assessed for replication in a Norwegian cohort (CONOR). RESULTS: We observed no significant association between genetic variants and prostate cancer survival. CONCLUSIONS: Common genetic variants with large impact on prostate cancer survival were not observed in this study. IMPACT: Future studies should be designed for identification of rare variants with large effect sizes or common variants with small effect sizes.

Funders

Research Categories

Main Subject Area

Fields of Research

Links & Metrics

NORA University Profiles

University of Copenhagen

Dimensions Citation Indicators

Times Cited: 20

Field Citation Ratio (FCR): 4.97

Relative Citation ratio (RCR): 0.8

Open Access Info

Bronze